Goldman Sachs Group Inc Arbutus Biopharma Corp Transaction History

Goldman Sachs Group Inc

  • $596 Billion
  • Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,075,948 shares of ABUS stock, worth $7.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,075,948
Previous 2,075,948 -0.0%
Holding current value
$7.16 Million
Previous $7.25 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025
BUY
$3.06 - $3.59 $4.72 Million - $5.54 Million
1,544,070 Added 290.31%
2,075,948 $7.25 Million
Q4 2024

Feb 11, 2025
SELL
$3.18 - $4.2 $90,722 - $119,821
-28,529 Reduced 5.09%
531,878 $1.74 Million
Q3 2024

Nov 14, 2024
BUY
$3.12 - $4.56 $1.26 Million - $1.84 Million
403,078 Added 256.2%
560,407 $2.16 Million
Q2 2024

Aug 13, 2024
SELL
$2.52 - $3.63 $43,787 - $63,074
-17,376 Reduced 9.95%
157,329 $486,000
Q1 2024

May 15, 2024
BUY
$2.26 - $2.92 $108,739 - $140,495
48,115 Added 38.01%
174,705 $450,000
Q4 2023

Feb 13, 2024
SELL
$1.69 - $2.54 $131,902 - $198,244
-78,049 Reduced 38.14%
126,590 $316,000
Q3 2023

May 14, 2024
BUY
$1.9 - $2.27 $148,293 - $177,171
78,049 Added 61.65%
204,639 $415,000
Q3 2023

Nov 14, 2023
SELL
$1.9 - $2.27 $33,206 - $39,672
-17,477 Reduced 7.87%
204,639 $415,000
Q2 2023

May 14, 2024
SELL
$2.24 - $3.06 $108,588 - $148,339
-48,477 Reduced 17.92%
222,116 $510,000
Q2 2023

Aug 14, 2023
SELL
$2.24 - $3.06 $108,588 - $148,339
-48,477 Reduced 17.92%
222,116 $510,000
Q1 2023

May 14, 2024
SELL
$2.23 - $3.1 $252,832 - $351,471
-113,378 Reduced 29.53%
270,593 $819,000
Q1 2023

May 11, 2023
SELL
$2.23 - $3.1 $252,832 - $351,471
-113,378 Reduced 29.53%
270,593 $819,000
Q4 2022

May 14, 2024
SELL
$1.91 - $2.85 $510,094 - $761,135
-267,065 Reduced 41.02%
383,971 $894,000
Q4 2022

Feb 13, 2023
SELL
$1.91 - $2.85 $510,094 - $761,135
-267,065 Reduced 41.02%
383,971 $894,000
Q3 2022

May 14, 2024
SELL
$1.88 - $2.88 $150,642 - $230,771
-80,129 Reduced 10.96%
651,036 $1.24 Million
Q3 2022

Nov 10, 2022
SELL
$1.88 - $2.88 $150,642 - $230,771
-80,129 Reduced 10.96%
651,036 $1.24 Million
Q2 2022

May 14, 2024
BUY
$1.98 - $3.17 $1.2 Million - $1.92 Million
604,575 Added 477.59%
731,165 $1.98 Million
Q2 2022

Aug 15, 2022
SELL
$1.98 - $3.17 $1.6 Million - $2.57 Million
-810,020 Reduced 52.56%
731,165 $1.98 Million
Q1 2022

May 16, 2022
BUY
$2.42 - $3.98 $2.05 Million - $3.37 Million
847,914 Added 122.31%
1,541,185 $4.59 Million
Q4 2021

Feb 14, 2022
BUY
$3.11 - $4.61 $1.26 Million - $1.87 Million
406,635 Added 141.86%
693,271 $2.7 Million
Q3 2021

Nov 10, 2021
BUY
$2.65 - $4.62 $759,585 - $1.32 Million
286,636 New
286,636 $1.23 Million

Others Institutions Holding ABUS

# of Institutions
191
Shares Held
111M
Call Options Held
866K
Put Options Held
608K
View Full List

About Arbutus Biopharma Corp

ABUS Quotes by TradingView
  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $517M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email